Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

since the pharmaceutical giant is one of the undisputed leaders in the exciting market for weight loss drugs. It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or ...

"It really points to challenges with insurance and cost that make these drugs less accessible ... for diabetes and Saxenda for weight loss. Because Eli Lilly's tirzepatide did not hit the market ...

U.S. stock futures are edging mostly higher as investors watch corporate earnings, Honeywell plans to split into three companies, and Qualcomm stock drops as its licensing revenue misses expectations.